CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS

Marc Ferrante  ¹     Laurent Peyrin-Biroulet  ²     Axel Dignass  ³     David T. Rubin  ⁴     Silvio Danese  ⁵     Geert R. D'Haens  ⁶     Kristina Kligys  ⁷     Sofie Berg  ⁷     Jasmina Kalabic  ⁸     Javier Zambrano  ⁸     Yafei Zhang  ⁸     Toshimitsu Fujii  ⁹     Remo Panaccione  ^10    
1 University Hospitals Leuven, Leuven, Belgium
² Nancy University Hospital, Vandoeuvre-les-Nancy, France
³ Agaplesion Markus Krankenhaus, Frankfurt/Main, Germany
⁴ University of Chicago Medicine, Chicago, United States
⁵ Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milan, Italy
⁶ AMC Amsterdam Inflammatory Bowel Disease Centre - Academic Medical Center, AMC Amsterdam Inflammator, Amsterdam, Netherlands
⁷ AbbVie Inc., North Chicago, United States
⁸ AbbVie, Ludwigshafen, Germany
⁹ Tokyo Medical and Dental University, Tokyo, Japan
¹⁰ University of Calgary, Calgary, Canada

Topic
IBD, Nurses, Primary Care

Session
Clinical trials in Crohn's disease

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)